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Abstract
Background: The outcome of leishmaniasis is an interplay between Leishamania and the host. Identifying
contributory host genetic factors is complicated by the variability in phenotype, ethnicity and parasite species.
Leishmaniasis is caused exclusively by L. donovani in Sri Lanka with localized cutaneous leishmaniasis (LCL) being
the predominant form. We report here an association study of human leucocyte antigen (HLA) class I and II genes
with LCL in Sri Lanka, the first on HLA associations in cutaneous leishmaniasis in a South Asian population.
Methods: An existing DNA repository of 200 each of patients and controls was typed for HLA-DQ by PCR-SSP. Next
generation sequencing-based typing for HLA-A, HLA-B and HLA-DRB1 alleles was done in a subset of 280 samples.
Association tests were performed on 28,489 genotyped and imputed SNPs spanning a region of 1.4 Mb across the
HLA genes. To compare our results with similar studies, we carried out a systematic review to document all HLA
associations reported to-date for cutaneous and muco-cutaneous leishmaniasis.
Results: DRB1*04 DQB1*02 (P = 0.03; Pc = 0.09), DRB1*07 DQB1*02 (P = 0.03; Pc = 0.09) haplotypes were absent in
patients. B*07 (P = 0.007; Pc = 0.13; OR = 0.36; 95 % CI = 0.17–0.77) allele and DRB1*15 DQB1*06 (P = 0.00; Pc < 0.01;
OR = 0.3; 95 % CI = 0.2–.0.6) haplotype were over represented in controls and DRB1*15 (P = 0.002; Pc = 0.01) allele
was over represented in patients. Two SNPs (rs281864595/rs1050517) in the antigen recognition region of HLA-B,
comprised a haplotype more frequent in controls (P = 0.04). The alleles identified by the systematic review to
predispose or to protect from cutaneous/mucocutaneous leishmaniasis remained highly heterogeneous in different
populations studied.
Conclusions: Our preliminary findings suggest a role for some class I and class II HLA genes in determining
predisposition to LCL in this population which should be corroborated with further studies. The systematic review
reiterates this need, as the purported susceptibility or protection gained by certain HLA alleles or haplotypes has
rarely been independently verified.
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Background
Leishmaniasis is an anthropo zoonotic disease with a
global incidence of approximately two million cases [1].
Caused by a protozoan parasite of the genus Leishmania
and transmitted by the sandfly, this is a disease with a
spectrum of phenotypes ranging from self-healing local-
ized skin lesions to potentially fatal visceral disease.
Classically, different species of Leishmania are impli-
cated in the distinct forms of the disease.
Cutaneous disease, even if not fatal can be chronic,
disfiguring and stigmatizing and bears the brunt of the
disease burden with 1.5 million new cases reported every
year [2]. The cutaneous form itself has a range of clinical
presentations with localised cutaneous leishmaniasis
(LCL) being the commonest. The severity of cutaneous
disease depends on both the extent of parasite replica-
tion and the relative induction of immunopathologic re-
sponses by the host. The genetic background is
considered the single most important host factor which
modulates these immune responses [3–6].
The human major histocompatibility complex (MHC)
gene cluster on the short arm of chromosome 6 has
been central to many studies investigating host genetic
factors as determinants of outcome of leishmaniasis.
The classical human leukocyte antigen (HLA) genes of
class I and II located within the MHC, encode molecules
identified for their role in presentation of antigens to
CD8+ and CD4+ T cells respectively. CD4+ T cells are
the major source of interferon (IFN)-γ which controls
parasite multiplication during the early phases of Leish-
mania infection [7, 8] whereas CD8+ T cells have been
described to contribute to IFN-γ production and the dif-
ferentiation of Th1 responses [9, 10]. Furthermore, local-
ised cutaneous lesions due to L. (V.) braziliensis or L.
(L.) amazonensis which demonstrated a balanced im-
mune response and healing, have been shown to have a
high prevalence of MHC class I restricted CD8+ T cells
by immunocytochemistry analysis [11, 12]. Hence, varia-
tions at HLA class I and II loci, with resultant variability
in interactions with parasite antigen, are likely to affect
susceptibility to leishmaniasis [4].
Knowledge on the role of HLA genes as determinants
of cutaneous leishmaniasis has mostly originated from
studies in South American populations, with the pre-
dominant causative parasite species implicated in these
infections being L. braziliensis [6, 13–16]. It has been
shown that several class I (HLA-B) and class II (HLA-
DQ) alleles are associated with susceptibility or protec-
tion to LCL in Venezuelan patients [13]. In a study
undertaken on Mexican Mestizos, DRB1*0407,
DPA1*0401 and DPB1*0101 were reported to be risk al-
leles while DPB1*0401 and DR2 were protective towards
LCL [15]. More recently, a study conducted in southern
Brazil reported a trend towards susceptibility to
cutaneous lesions for several class 1 (HLA-B) and class
II (HLA-DRB1) alleles while another HLA-B allele
tended to be protective [16]. A single study on patients
of South East Asian origin with cutaneous leishmaniasis
due to Leishmania (V.) guyanensis reported a decrease
of HLA-Cw7 antigen [17].
In contrast, the focus on South Asian populations has
mainly been on the visceral form of the disease [18].
Leishmaniasis in Sri Lanka, until recently has been ex-
clusively of the localised cutaneous type with over 2500
cases being diagnosed during the last 10 years [19] with
numbers reported to the health system considered to be
largely under-represented [20]. The causative parasite of
both cutaneous and visceral disease has been identified
as L. donovani MON 37; a zymodeme very closely re-
lated to L. donovani MON 2 which causes visceral dis-
ease in neighbouring India [21, 22]. However, LCL
continues to be the predominant phenotype in the island
in both known and new foci [19, 23, 24].
Identifying human genetic factors which operate in di-
verse backgrounds of parasite species and host ethnicity
would contribute to understanding the complex patho-
genic mechanisms underlying leishmaniasis and help
identify common molecular pathways for treatment and
control. We have earlier reported the observation that
LCL in Sri Lanka appears to more commonly affect
those of Sinhalese ethnicity [25]. A previous study by us
which investigated selected polymorphisms of TNF, LTA
and SLC11A1 genes did not show any association with
LCL in this population [26]. The aim of this case control
study was to investigate the association of HLA class I/II
loci with LCL in the local Sri Lankan population. We
also carried out a systematic review of published litera-
ture to document all similar associations reported in
other geographical regions and compared it with our
findings.
Methods
Study population and DNA samples
The study was carried out using an already established
DNA resource for conducting host genetic studies on
leishmaniasis in Sri Lanka. Briefly, the study population
comprised 200 unrelated patients with a laboratory con-
firmed diagnosis of LCL and 200 healthy, unrelated con-
trols matched for age, gender and ethnicity. The patients
were recruited at the referral clinic conducted by the
Centre for Training, Research and Diagnosis of Leish-
maniasis of University of Colombo and were from 11
districts of Sri Lanka; with the highest numbers from
Matara and Hambantota districts in the Southern prov-
ince followed by Anuradhapura district in the North
Central province. Controls were recruited from the same
endemic regions during the same time period as the pa-
tients. Controls were excluded if they had a previous
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history or diagnostic evaluation suggestive of LCL. All
subjects were Sinhalese. Genomic DNA was extracted
from peripheral blood lymphocytes using QIAamp DNA
Mini Kit (Qiagen, USA) according to the manufacturer’s
instructions. Recruitment of participants and establish-
ment of the DNA resource has been described before
[25].
HLA typing
HLA-DQB1 alleles were determined by a PCR sequence-
specific priming (SSP) technique using AllSet Gold SSP
low resolution kit according to the specifications of the
manufacturer (Invitrogen, USA). PCR products were an-
alyzed on a 2.0 % agarose gel stained with ethidium
bromide (0.5 g/ml) for specific amplification patterns
and alleles were assigned with SSP UniMatch (v5.1) soft-
ware. Genotyping was performed at the Human Genetics
Unit, Faculty of Medicine, University of Colombo. Exons
2 to 3 of HLA-A and HLA-B genes and Exons 2 to 4 of
HLA-DRB1 gene were sequenced in a subset of 140 each
of patients and controls, on an Ion Proton next gener-
ation sequencing platform at a commercial sequencing
laboratory [27]. The HLA alleles were analyzed and
assigned at the same facility, by aligning against refer-
ence sequences of IMGT/HLA database and using an in
house protocol adapted from published methods [28].
Construction of a SNP panel of the HLA region
The variant calls derived from sequencing reads were
used to construct a discovery SNP panel for cases and
controls. All bi allelic SNPs identified in any of the sub-
jects were extracted and included in the panel. Each in-
dividual sequence was analysed for the presence of the
SNPs in the panel and zygosity at each SNP position was
determined accordingly using custom built scripts. Fur-
ther to this, variants within the HLA region on chromo-
some 6 from 6_29910603 to 6_31324183 were imputed
in our discovery panel using IMPUTE2 (version2.3.1)
[29] and an integrated dataset from 1000 Genomes
Phase 1 [30, 31] as the reference panel.
Statistical analysis
HLA allele and haplotype frequencies were estimated by
the maximum likelihood method, using the Arlequin
(version 3.5) software [32]. Exact tests of Hardy-
Weinberg equilibrium for each locus were performed
using the same. The frequencies of multi locus haplo-
types were estimated under an unknown gametic phase.
The distribution of these alleles and haplotypes was
compared with Pearson χ2 test with Yates correction and
Fisher exact test with SPSS (version 15.0). The resulting
P values were corrected for multiple comparisons (Pc)
by the false discovery rate method [33] and significance
was determined at P < 0.05. Both adjusted and
unadjusted P values are presented. All statistical analyses
were performed at the two digit-allele group level.
Comparison of SNPs between cases and controls was
carried out using PLINK [34, 35]. SNPs were tested at
allelic level and genotype level under dominant, additive
and recessive models of inheritance. P value of 0.05 ad-
justed for multiple testing by FDR method was consid-
ered as significant. Haplotypes were constructed for
selected SNPs and also compared between cases and
controls using the same software. Functional prediction
of the SNPs was carried out using standard bioinfor-
matic tools including SNPNexus [36], Mutation Taster
[37] and SIFT [38] and further analysed with PDB,
Structure and InterPro databases [39–41]. All genomic
positions reported correspond to NCBI SNP build 137.
Systematic review
The aim of the systematic review was to document all
HLA associations reported in literature that increased
susceptibility to cuteanous/mucocutaneous leishmaniasis
and to correlate these findings with our results.
We searched PUBMED, Web of Science (SCI),
EMBASE and CINAHL for research on HLA associa-
tions with different clinical types of leishmaniasis. All
databases were searched with keywords “Leishmania*”
AND “HLA”, “Leishmania*” AND “Histocompatibility”
in title, keywords and abstracts. All relevant studies on
human populations (or case control/family studies) were
selected for further review without time or language
Table 1 Summary of demographic features of patients with
limited Cutaneous Leishmaniasis















Southern province 126 (63.0)
North Central province 40 (20.0)
Occupation
Military personnel 56 (28.0)
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restrictions. We used the software Endnote X7 (Thom-
son Reuters, Carlsbad, CA 92011, USA) to filter articles.
The searches had a low specificity to not to miss any
relevant articles. We read all abstracts independently,
and identified key articles by consensus. Full articles
were obtained for all relevant studies except on one oc-
casion where the authors could not be contacted. The
article selection was conducted according to PRISMA
requirements (Additional file 1: Figure S1).
Results
The present study investigated a potential association
between LCL and class I and II HLA loci in a South
Asian population by comparing the distribution of HLA-
A, HLA-B, HLA-DRB1 and HLA-DQB1 alleles in pa-
tients and healthy controls. The analysis was comple-
mented by comparing the distribution of SNPs in the
above HLA gene regions between the two groups.
Clinical characteristics of patients
A majority of patients presented with painless, single
and dry ulcers which had been present for less than
6 months. While 20 % of patients had multiple lesions,
5.5 % of patients had other affected family members.
The characteristics of the patients have been described
in detail previously [25] and demographic details are
summarized in Table 1.
Distribution of HLA alleles
The frequencies of all identified HLA (A, B, DRB1 and
DQB1) alleles in patients with LCL and the control
group are listed in Table 2. B*07 followed by B*40 were
the two most common HLA-B alleles in both patients
and controls out of 10 alleles which were common to
both groups. At the DRB1 locus DRB1*15 was the only
allele seen in patients while 7 alleles were seen in con-
trols with DRB1*15 being present in the majority. The
DQB1 alleles showed a comparable distribution in pa-
tients and controls except for the absence of DQB1*04
in patients. Differences in distribution were observed in
several alleles with B*07 (25 % vs 48 %; P = 0.007; Pc =
0.13; OR = 0.36; 95 % CI = 0.17–0.77) more frequent in
controls and DRB1*15 (100.0 % vs 76.0 %; P = 0.002; Pc
Table 2 HLA class I and class II allele distribution in patients
with localised cutaneous leishmaniasis and population controls
(n- 140 patients and 140 controls)
Allele frequency
Allele Patients Controls P value* Pc** OR (95 % CI)
HLA-Aa 2n = 18 2n = 62
Aa02 0.4444 0.2581 0.13 0.29 2.3 (0.77–6.84)
Aa03 0.1667 0.0807 0.28 0.43 2.3 (0.49–10.64)
Aa11 0.0556 0.0161 0.39 0.44 3.6 (0.21–60.41)
Aa23 0.0556 0.0161 0.39 0.39 3.6 (0.21–60.41)
Aa24 0.1111 0.0484 0.33 0.43 2.46 (0.38–15.99)
Aa29 0.0000 0.1774 0.06 0.28 NAa
Aa31 0.0556 0.1774 0.2 0.36 0.3 (0.03–2.27)
Aa33 0.1111 0.0161 0.09 0.27 7.6 (0.65–89.5)
Aa68 0.0000 0.2097 0.03 0.31 NAa
HLA-B 2n = 60 2n = 62
Ba07 0.25 0.4839 0.007 0.13 0.36 (0.17–0.77)
Ba08 0.0333 0.0161 0.62 0.73 2.1 (0.19–23.83)
Ba14 0.0167 0.0000 0.49 0.85 NA
Ba15 0.0833 0.0484 0.44 0.83 1.8 (0.41–7.84)
Ba25 0.0167 0.0000 0.49 0.78 NA
Ba27 0.0333 0.0323 0.97 1.02 1.03 (0.14–7.6)
Ba35 0.1167 0.0645 0.32 0.67 1.92 (0.53–6.92)
Ba37 0.0167 0.0000 0.49 0.72 NA
Ba38 0.0167 0.0645 0.18 1.16 0.25 (0.03–2.26)
Ba39 0.0333 0.0000 0.24 1.14 NA
Ba40 0.1167 0.0968 0.72 0.81 1.23 (0.39–3.91)
Ba42 0.0000 0.0484 0.24 0.81 NA
Ba44 0.1 0.0323 0.16 1.52 3.33 (0.64–17.22)
Ba51 0.0333 0.0807 0.26 0.62 0.39 (0.07–2.11)
Ba52 0.0333 0.0000 0.24 0.91 NA
Ba53 0.0167 0.0000 0.49 0.67 NA
Ba55 0.0167 0.0000 0.49 0.62 NA
Ba57 0.0333 0.0000 0.24 0.76 NA
Ba58 0.0333 0.0323 1.0 1.0 1.03 (0.14–7.59)
HLA-DRB1 2n = 34 2n = 88
DRB1a03 0.0000 0.0114 1.0 1.17 NA
DRB1a04 0.0000 0.1023 0.06 0.21 NA
DRB1a07 0.0000 0.0682 0.18 0.43 NA
DRB1a09 0.0000 0.0227 1.0 1.75 NA
DRB1a14 0.0000 0.0227 1.0 1.4 NA
DRB1a15 1.0000 0.7614 0.002 0.01 NA
DRB1a16 0.0000 0.0114 1.0 1.0 NA
HLA-DQB1 2n = 358 2n = 346
DQB1a02 0.1229 0.159 0.11 0.28 0.71 (0.46–1.08)
DQB1a03 0.2458 0.2139 0.2 0.34 1.25 (0.88–1.78)
Table 2 HLA class I and class II allele distribution in patients
with localised cutaneous leishmaniasis and population controls
(n- 140 patients and 140 controls) (Continued)
DQB1a04 0.0000 0.0116 0.06 0.29 NA
DQB1a05 0.3045 0.3035 0.89 0.89 0.98 (0.71–1.35)
DQB1a06 0.3268 0.3121 0.62 0.78 1.08 (0.79–1.49)
2n, where n is the number of individuals successfully genotyped at each locus
*P value was calculated by Pearson’s chi-square test or Fisher’s exact test
**Pc, corrected P values for the number of alleles tested, calculated using the
False Discovery Rate method
ainterpretations cannot be made due to limited sample size
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= 0.01) that was over represented in patients. Overall,
successful allele identification could not be performed
for many samples in both control and patient groups
due to some regions of DNA in the samples being re-
fractory to amplification. Especially the number of alleles
identified for HLA-A was limited and therefore it is not
possible to draw conclusions about HLA-A allele distri-
bution in cases and controls.
Distribution of HLA haplotypes
The distribution of specific 2 locus haplotypes is shown
in Table 3. The most common haplotype was DRB1*15-
DQB1*06 in both patients and controls. Haplotypes
DRB1*04-DQB1*02 (0.0 % vs 1.8 %; P = 0.03; Pc = 0.09)
and DRB1*07-DQB1*02 (0.0 % vs 1.8 %; P = 0.03; Pc =
0.09) were absent in controls while DRB1*15-DQB1*06
(5.8 % vs 15.2 %; P < 0.01 Pc < 0.01; OR = 0.3; 95 % CI =
0.2–.0.6) was present in a higher proportion of controls.
Association analysis of SNPs in HLA region
The discovery SNP panel consisted of 28,489 SNPs span-
ning a region of 1.4 Mb on chromosome 6 extending
from 6:29910603 to 6:31324183. After quality control 14
SNPs in 92 cases and 106 controls remained for analysis.
None of the SNPs were associated with LCL at allelic
level or genotypic level under different models of inher-
itance. At haplotype level, a haplotype consisting of al-
leles of two SNPs at 6:31324638 (rs281864595) and
6:31324643 (rs1050517) was seen to be higher in the
controls (84.0 % vs; 93.3 %; P = 0.04). Annotation details
of the SNPs which constituted the haplotype which
tended to confer protection are given in Table 4.
Structural analysis in relation to above, showed the
amino acids implicated by above SNPs to be situated in
the alpha 1 –alpha 2 domain of HLA*B which comprises
its peptide binding region (Additional file 2: Figure S2).
Systematic review
The initial search with specified search methods yielded
601 abstracts. After removing duplicates and selecting
studies that had reported on associations of HLA allele
frequency in case control studies, 11 articles remained.
Further four articles were excluded as they discussed vis-
ceral leishmaniasis. We have summarized the findings of
these studies in Table 5. Overall, the reported alleles that
purportedly increased or reduced susceptibility to cuta-
neous/mucocutaneous leishmaniasis remained highly
heterogeneous in different populations studied.
Discussion
We studied the association of variations at HLA class I
(HLA-A, HLA-B) and HLA class II (HLA-DRB1, HLA-
DQB1) loci with susceptibility to localised cutaneous
leishmaniasis in Sinhalese in Sri Lanka. The results pre-
sented in this report are, to our knowledge, the first on
HLA associations in cutaneous leishmaniasis in a South
Asian population.
The distribution of HLA alleles showed 7 alleles of
HLA-A, 18 alleles of HLA-B and 4 alleles of HLA-DQB1
to be present in patients with LCL. Notably, the HLA-B
locus was more polymorphic in the patients than in the
control population. Eventhough only HLA-DRB1*15 al-
lele was observed in the patients, this is likely to be due
to the limited sample number, as evident by the poly-
morphic nature of the locus in the larger control group.
The overall distribution of alleles in the controls con-
forms to previous reports from the country [42] and
adds to the limited data available on HLA polymor-
phisms in this population.
The case control analysis did not show any statistically
significant associations between HLA markers and LCL
after correcting for multiple testing. However, compari-
sons of trends observed in this study with findings from
other populations are noteworthy. For instance, the al-
lele frequency of HLA-B*07 (P = 0.007; Pc = 0.13; OR =
0.36; 95 % CI = 0.17–0.77) was higher in controls sug-
gesting a protective tendency by this allele. Interestingly
HLA Bw22, which is similar to HLA-B*07 in the amino
acid sequence at alpha 1-helix [43], has been shown to
be a risk factor for cutaneous leishmaniasis due to L.
Table 3 Distribution of HLA DRB1*-DQB1* haplotypes in patients
with localised cutaneous leishmaniasis and population controls
Haplotype frequencya (N)
Haplotype Patients Controls P Pcb OR (95 % CI)
DRB1*04 DQB1*02 0.0000 (0) 0.0185 (5) 0.03 0.09 NA
DRB1*07 DQB1*02 0.0000 (0) 0.0185 (5) 0.03 0.09 NA
DRB1*15 DQB1*02 0.0000 (0) 0.0148 (3) 0.12 0.18 NA
DRB1*15 DQB1*03 0.0255 (6) 0.0277 (8) 0.56 0.56 0.73 (0.25–2.1)
DRB1*15 DQB1*05 0.0328 (8) 0.0501 (14) 0.18 0.22 0.55 (0.23–1.3)
DRB1*15 DQB1*06 0.0584 (16) 0.1519 (41) 0.00 0.00 0.3 (0.2–.0.6)
N indicates the number of patients or controls with the given haplotype
aOnly the haplotypes present at a minimum of 0.01 % in the patients or
controls are listed
bPc, corrected P values for the number of alleles tested, calculated using the
False Discovery Rate method
Table 4 SNPs comprising the haplotype associated with protection to LCL
Position dbSNP ID Gene Amino acid change Predicted function SIFT prediction (confidence)
6:31324638 rs281864595 HLA-B Non synonymous Coding Damaging (low)
6:31324643 rs1050517 HLA-B Synonymous Coding -
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Table 5 HLA associations for cutaneous/muco-cutaneous leishmaniasis from case control studies conducted to-date
Study Location Type of
leishmaniasis
Sample size Associations for
susceptibility











Brazil Cutaneous 160 patients DRB1*13 1.66; (1.08–2.56) B*45 P = 0.01
















Mexico Cutaneous 65 patients DRB1*0407 2.92 (1.68–5.06) DPB1*0401 0.38 (0.21–0.67)


















Sri Lanka Cutaneous 200 patients DRB1*15 p = 0.002, Pc = 0.01 A*68 P = 0.03;
Pc = 0.31
200 controls




























A*28 P = 0.0018 B*15 0.0062
Bw22 P = 0.012
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braziliensis in Venezuelans [13]. The same study re-
ported a protective effect conferred by HLA-B15,
whereas the frequency of HLA-B15 was twice that of
controls in our patients. Ribas-Silva et al. [16], investigat-
ing genetic susceptibility to different clinical manifesta-
tions of American cutaneous leishmaniasis in southern
Brazil, reported HLA B*35 and B*44 to confer suscepti-
bility and B*45 to confer protection against cutaneous
lesions. Both HLA B*35 and B*44 were over represented
in our patient group but did not reach significant
proportions.
At the HLA-DQ locus, DQw3 (DQB1*03) and DQw8
(DQB1*0302) have been associated with susceptibility to
LCL [13] whereas the present study showed an equiva-
lent distribution of DQB1*03 between the two groups. In
contrast to the current study where DRB1*15 (P = 0.002;
Pc = 0.01) appeared to be a risk allele, DR2 serotype
which encompasses DRB1*15 and DRB1*16 was found
to be protective in Mexican Mestizos [15]. Further,
DRB1*13 and DRB1*04 were considered risk factors in
this same population and in Brazilians [16] respectively.
The small sample number is a limitation of this study.
This may lead to a bias in estimating allele and haplo-
type frequencies and thus caution should be exercised in
extrapolating them to the study population. This may
also explain some of the observations made, for instance
the patient group being monomorphic at the HLA-DRB1
locus, and calls for replication of findings in a bigger co-
hort in validating the significant associations involving
this locus.
The apparently contradictory results for the same
locus in different global populations as we report here, is
a common occurrence in genetic association studies.
These differences most probably reflect the LD patterns
across the gene regions under focus, with the clinical
outcome being the concerted effect of several loci, some
of which may have not been considered in the particular
study. This variability is further compounded by the ex-
tensive polymorphism in the HLA genes [44]. However,
notably the only genome wide association study to be
conducted on leishmaniasis reported risk variants for
the visceral phenotype in the HLA-DRB1-HLA-DQA1
region, which were common to population groups across
different geographical areas and affected by different
parasite species (Fakiola et al. [18]). Further, patients
with other affected family members may indicate shared
living environment or a true genetic association. Thus,
complimenting population based case control analyses
such as that undertaken in the present study, with
multi-case family based linkage analyses and transmis-
sion disequilibrium testing would also strengthen the
findings.
The systematic review showed that there are only a
handful of studies that have assessed the HLA poly-
morphism in cases and controls worldwide. Most of
these studies are from Latin America and our study in
fact is the first from Asia on cutaneous leishmaniasis.
There are several studies that have assessed HLA poly-
morphism in visceral leishmaniasis including a large
scale multicentre study in Brazil and India [45], but not
for cutaneous leishmaniasis. It is also noted that while
there are two studies that explicitly stated no HLA asso-
ciations for visceral leishmaniasis (out of 4 studies) when
compared with controls [46, 47], all studies that assessed
the same for cutaneous/muco-cutaneous leishmaniasis
report otherwise. There can be reporting bias with non-
publication of negative results but even in the two stud-
ies that showed a significant association it was just lim-
ited to 3 HLA alleles in both studies combined [45, 48].
The synthesis of observations (Table 5) shows that the
purported susceptibility or protection gained by certain
HLA alleles or haplotypes has rarely been independently
verified by subsequent studies except for few exceptions
(DR2 serotype). There can be several reasons for this.
Firstly, the studies are few in number and small in sam-
ple size. Secondly, they are spread across different coun-
tries/geographical regions that have populations isolated
from each other with plausibly different baseline HLA
allele frequencies in the population. Thirdly, the Leish-
mania species (hence antigens) in each of these regions
differ which can lead to heterogeneity in host response.
Overall, it raises the importance of screening individual
populations locally to identify protective and susceptible
characteristics of host genome which would be import-
ant to design effective vaccines for local populations.
Conclusions
Overall, several of the alleles in the HLA-B region which
have been associated with susceptibility or protection to-
wards cutaneous leishmaniasis in other populations,












Cutaneous 32 cases Cw7 p = 0.01
55 controls
a
Full article was not available
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were also shown to differ between patients and controls
of our study group. The two SNPs on HLA-B gene,
which result in a haplotype found to be more frequent
in controls as shown by the complementary SNP ana-
lysis, have not been widely reported to aid definitive
conclusions. Nevertheless, the fact that these implicate
two adjacent amino acids in the alpha1 – alpha2 region
of HLA*B which comprises its antigen recognition re-
gion, suggests candidate loci to be considered in ex-
panded work in this study group.
Further studies in this population, on larger sample
numbers conferring better statistical power will be re-
quired to support the findings of this study. The findings
should also be complemented with higher resolution
HLA typing, high density SNP analyses of the HLA re-
gion and also functional studies on interactions between
host immune response cells and parasite antigens in a
HLA restricted setting.
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Additional file 1: Figure S1. PRISMA flow chart for systematic review.
(DOCX 76 kb)
Additional file 2: Figure S2. Three dimensional model of HLA-B
protein based on PDB entry 1HSA (DOI:10.2210/pdb1hsa/pdb). Amino
acids at positions 55 and 57 in the alpha1 and alpha2 domains of the
molecule which constitute the antigen recognition region are highlighted.
(TIF 376 kb)
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